GLP sales in focus in Novo's Q3 figures after major guidance upgrade - important data to come
One of the significant share price drivers for Novo Nordisk will come later in November when the company publishes detailed data from a cardiovascular study with Wegovy.
by marketwire
Novo Nordisk has taken analysts and the market by surprise with preliminary growth figures and another significant upward adjustment of the guidance for 2023 ahead of the third quarter results, Barclays informs in a note, raising its estimates following Novo Nordisk’s guidance upgrade on October 13.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
